The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

Douglas S Corwin; Peter T Ender; Nitasa Sahu; Ryan A Durgham; Dennis M McGorry Jr; Awan Rahman; Jill Stoltzfus; Jeffrey A Jahre

doi:10.1093/ofid/ofab305

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

Open Forum Infect Dis. 2021 Jun 10;8(7):ofab305. doi: 10.1093/ofid/ofab305. eCollection 2021 Jul.

Authors

Douglas S Corwin¹, Peter T Ender², Nitasa Sahu¹, Ryan A Durgham³, Dennis M McGorry Jr⁴, Awan Rahman¹, Jill Stoltzfus⁵, Jeffrey A Jahre²

Affiliations

¹ Section of Pulmonary and Critical Care, Department of Medicine, St Luke's University Health Network, Bethlehem, Pennsylvania, USA.
² Section of Infectious Diseases, Department of Medicine, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.
³ Temple/St. Luke's School of Medicine, Bethlehem, Pennsylvania, USA.
⁴ Department of Family Medicine, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.
⁵ Graduate Medical Education, Data Management and Outcomes Assessment, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.

Abstract

Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.

Keywords: COVID-19; bamlanivimab; outcomes; treatment.